MONMOUTH JUNCTION, N.J.–(BUSINESS WIRE)–MicroDose Therapeutx, Inc. and Moerae Matrix, Inc. announced today that they have signed a collaboration agreement to develop a dry powder inhalation product of Moerae’s novel MK2 inhibitor, MMI-0100, for the treatment of idiopathic pulmonary fibrosis (IPF), a serious and fatal lung disease for which there are no approved treatments in the U.S. The collaboration will involve the development and supply of a pulmonary drug delivery system for Moerae and/or its partners utilizing MicroDose’s proprietary inhaler technology in support of chronic administration.
“We are pleased to be partnering with a recognized industry leader in pulmonary drug delivery to advance development of MMI-0100 for IPF,” said Cynthia Lander, PhD, Chairman and Chief Executive Officer of Moerae Matrix. “MicroDose’s piezo-driven dry powder inhaler platform is the optimal technology for delivering our first-in-class peptide therapeutic for treatment of IPF.”
Commenting from MicroDose, Scott Fleming, Sr. Vice President, Sales and Marketing said, “Moerae has assembled an impressive team to advance this promising treatment approach for this debilitating disease and we are pleased to be able to contribute to its advancement. This collaboration in IPF expands the utilization of MicroDose’s inhalation technology into yet another extremely important disease area.”
Read the entire article at:
For more information about Idiopathic Pulmonary Fibrosis please visit: www.ipftoday.com